Miraclid

(Ulinastatin)

ApprovedSmall molecule

Ulinastatin is used to reduce inflammation and prevent tissue damage in conditions like acute pancreatitis and sepsis, where the body's own enzymes are causing harm.[2] Miraclid is currently approved and in use across 19 indications[4].[1]

Miraclid is one of 415 small molecule programs targeting Acute Pancreatitis. It is currently in Approved.

Indications

Total Trials

Active Trials

414

Competitors

Pipeline

Status by Indication[4][1]

Indication

Acute PancreatitisActive, not recruiting

Systemic Inflammatory Response SyndromeActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

HemorrhageUnknown

MortalityActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

SepsisActive, not recruiting

EncephalopathyActive, not recruiting

Inflammatory ResponseActive, not recruiting

Coronary Artery BypassActive, not recruiting

Acute PancreatitisApproved

Active, not recruiting

Systemic Inflammatory Response SyndromePhase 3

Active, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

HemorrhagePreclinical

Unknown

MortalityApproved

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

SepsisPhase 3

Active, not recruiting

EncephalopathyPreclinical

Active, not recruiting

Inflammatory ResponsePreclinical

Active, not recruiting

Coronary Artery BypassPreclinical

Active, not recruiting

Showing 10 of 18 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Approved

1 2

Tricor

JJagotec

Preclinical

1 3

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 4

Blood Taken

HHospices Civils de Lyon

Preclinical

1 5

Selenium

SSWOG Cancer Research Network

Preclinical

1 6

Antithrombin-III

Octapharma

Preclinical

1 7

MRNA COVID-19 Vaccine

Novartis

Preclinical

4 8

Standard Preparation

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Preclinical

1 9

COVID-19 Vaccines

UUniversity of British Columbia

Hymecromone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ANot yet recruiting

Aortic Dissection

NCT07382375

Q2 2028

PreclinicalNot yet recruiting

Intra-Abdominal Infection

NCT07672496

Clinical

Trials by Indication[1]

Aortic dissection3 trials

Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)

Enrolling by invitation·NNanjing Medical University·N/A·NCT06966687·200 enrolled

Mechanism and Early Intervention Research on ALI During Emergence Surgery of Acute Stanford A Aortic Dissection

Unknown status·—·N/A·NCT01894334·220 enrolled

AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection

Not yet recruiting·NNanjing Medical University·N/A·NCT07382375·300 enrolled

Cardiac Surgery3 trials

Protective Effect in Cardiac Surgery Patients

Unknown status·SShanghai Zhongshan Hospital·N/A·NCT04028024·90 enrolled

Ulinastatin's Anti-inflammatory Reaction in Cardiac Surgery

Completed·KKonkuk University Medical Center·Phase 4·NCT01518569·26 enrolled

Hemostatic Effects of Ulinastatin and Tranexamic Acid in Cardiac Surgery

Completed·—·N/A·NCT01060189·426 enrolled

Inflammatory Response2 trials

Protective Effect of Ulinastatin Against Negative Inflammatory Response and Organ Dysfunction After Acute Type a Aortic Dissection Surgery (PANDA I)

Completed·NNanjing Medical University·N/A·NCT04711889·203 enrolled

Effects of Ulinastatin on Inflammatory Response During ECMO Support

Unknown status·NNanfang Hospital, Southern Medical University··NCT04990752·144 enrolled

Cardiopulmonary Bypass2 trials

Ulinastatin Improves Postoperative Oxygenation After Cardiopulmonary Bypass

Completed·KKonkuk University Medical Center·Phase 4·NCT03154814·80 enrolled

Ulinastatin Improves and Prevents Cardiac Dysfunction Induced by Cardiopulmonary Bypass

Completed·QQin Zhang·N/A·NCT05534802·236 enrolled

Acute Respiratory Distress Syndrome2 trials

Prevention of Ulinastatin on Acute Respiratory Distress Syndrome (ARDS)

Completed·PPeking University Third Hospital·N/A·NCT03089957·840 enrolled

The Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)

Unknown status·TTechpool Bio-Pharma Co., Ltd.·Phase 2·NCT02895191·60 enrolled

17 more indications

Hepatocellular Carcinoma1 trial

Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)

Completed·—·N/A·NCT01643447·200 enrolled

Injury1 trial

Ulinastatin in Inhalation Lung Injury

Unknown status·—·Phase 2·NCT01287806·120 enrolled

Nasopharyngeal Carcinoma1 trial

Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients

Completed·SSun Yat-sen University·Phase 3·NCT03387774·179 enrolled

Encephalopathy1 trial

Ulinastatin Treatment Reduces the Incidence of Sepsis-associated Encephalopathy

Completed·SShusheng Li··NCT07090278·2,734 enrolled

Ulinastatin1 trial

Post-market Safety Reassessment of Ulinastatin for Injection

Unknown status·TTechpool Bio-Pharma Co., Ltd.··NCT02520570·10,000 enrolled

Systemic Inflammatory Response Syndrome1 trial

Clinical Efficacy of Ulinastatin for Treatment of Sepsis With Systemic Inflammatory Response Syndrome

Unknown status·HHuashan Hospital·Phase 3·NCT05391789·120 enrolled

Pediatric Patients1 trial

Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery

Unknown status·TTechpool Bio-Pharma Co., Ltd.·Phase 4·NCT02527811·450 enrolled

Laparoscopic1 trial

Effect of Ulinastatin on Postoperative Renal Function in Patients Undergoing Robot-assisted Laparoscopic Partial Nephrectomy

Completed·YYonsei University·N/A·NCT02258906·66 enrolled

Septic Shock1 trial

Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China

Completed·PPeking Union Medical College Hospital·Phase 4·NCT02647554·347 enrolled

COVID-191 trial

Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients

Withdrawn·SStanford University·Phase 1/2·NCT04393311

Cognitive Dysfunction1 trial

Ulinastatin Improves Post-Cardiac Surgery Cognitive Dysfunction

Completed·QQin Zhang··NCT06268249·7,065 enrolled

Mortality1 trial

Role of Ulinastatin in Preventing Severe Sepsis and Consequent Morbidities and Mortality

Unknown status·JJinnah Postgraduate Medical Centre·Phase 4·NCT05895240·175 enrolled

Coronary Artery Bypass1 trial

The Effect of Ulistin on Acute Renal Injury in Patients Undergoing OPCAB (Off Pump Coronary Artery Bypass): a Propensity Score Matched Study

Unknown status·—·N/A·NCT04473144·500 enrolled

Acute Pancreatitis1 trial

Ulinastatin in Severe Acute Pancreatitis

Suspended·TTechpool Bio-Pharma Co., Ltd.·Phase 4·NCT01132521·252 enrolled

Aortic Valve Replacement1 trial

Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement

Completed·YYonsei University·Phase 4·NCT00944385

Muscle Relaxants1 trial

Effect of Ulinastatin on the Action of Nondepolarising Muscle Relaxants Rocuronium / Cisatracurium

Completed·HHuazhong University of Science and Technology·Preclinical·NCT05716256·120 enrolled

Intra-abdominal Infection1 trial

A Single-Center Randomized Controlled Pilot Study on the Effect of Ulinastatin on Systemic Immune and Inflammatory Response in Patients With Complicated Intra-Abdominal Infection

Not yet recruiting·FFujian Medical University Union Hospital·Preclinical·NCT07672496·165 enrolled

Sources

References

[1]
ClinicalTrials.gov — 29 trial records for Ulinastatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Miraclid drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ulinastatin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ulinastatin. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Techpool Bio-Pharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: TTechpool Bio-Pharma Co., Ltd.

Miraclid

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Trials by Indication[1]

Aortic dissection3 trials

Cardiac Surgery3 trials

Inflammatory Response2 trials

Cardiopulmonary Bypass2 trials

Acute Respiratory Distress Syndrome2 trials

Hepatocellular Carcinoma1 trial

Injury1 trial

Nasopharyngeal Carcinoma1 trial

Encephalopathy1 trial

Ulinastatin1 trial

Systemic Inflammatory Response Syndrome1 trial

Pediatric Patients1 trial

Laparoscopic1 trial

Septic Shock1 trial

COVID-191 trial

Cognitive Dysfunction1 trial

Mortality1 trial

Coronary Artery Bypass1 trial

Acute Pancreatitis1 trial

Aortic Valve Replacement1 trial

Muscle Relaxants1 trial

Intra-abdominal Infection1 trial

References

Drug Info

Quick Facts

Related News